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Summary.-Doxorubicin in a dose of 60 mg/M2 has been used in the treatment of 23
patients with advanced malignant disease, 18 of whom had carcinoma of the breast.
The drug has significant clinical activity on its own, prolonged dosage may be
required to obtain a response, and there is a risk of cerebral metastases becoming
manifest during treatment which is otherwise successful. Cardiac toxicity appears
to be acceptably low with this dose regimen.
THE EFFECTIVENESS of doxorubicin
(Adriamycin) as an antitumour agent is
now becoming established. The early
clinical work from Italy (Bonadonna et al.,
1969) is expanded and supported by the
collated results from the N.C.I. trials
reported by Blum and Carter (1973). Its
effectiveness in acute lymphatic leukaemia
seems to be similar to that ofdaunorubicin
(Whitehouse et al., 1972), but it is less
effective in acute myeloid leukaemia.
The main interest lies in its use in solid
tumours.
MATERIALS AND METHODS
A series of 23 patients is presented, 18
with breast carcinoma, one with malignant
melanoma, one with reticulum cell sarcoma,
one with adamantinoma, one with carcinoma
of thyroid gland and one with metastases
from an undisclosed primary. In each case
doxorubicin was given in a dose of 60 mg/M2
by injection into the tubing of a fast running
saline drip. The dose was not repeated in
less than 3 weeks because it was thought that
more frequent administration might lead to
accumulation in tissues with consequent
increase in toxicity (Middleman, Luce and
Frei, 1971). Parallel pharmacological studies
by Wilkinson and Mawer (1973) have con-
firmed the slow elimination.
At each visit the patient was assessed for
unwanted side-effects. In addition to clinical
details which included cardiovascular examin-
ation, a full blood count and electrocardio-
graphy were carried out. The biochemical
profile was checked less frequently.
RESULTS
All of the 18 patients with breast
carcinoma had advanced disease and had
either failed to respond to, or had relapsed
after, conventional therapy using surgery,
radiotherapy, hormones and cytotoxic
drugs. Only 14 patients had an adequate
trial of 3 or more doses of the drug and of
these 14 only 2 showed a response consist-
ing of 50%o or more tumour regression
which was sustained for at least one
month. Five additional patients had a
response of less than 5000. In all 7 cases
the response was in soft tissue deposits.
In one patient a response was not seen
until 4 months had elapsed and she then
obtained a better than 500% regression
which has been maintained for over one
year (Table I).
It is of interest that 2 responders
developed cerebral metastases whilst the
disease elsewhere remained under control
-in one case at 2 months and in the
other at 4 months. This is in accord with
pharmacological studies (Wilkinson and
Mawer, 1973) which show that, in rats,
doxorubicin is poorly concentrated in
the brain. Further, Benjamin, WiernickA PRELIMINARY TRIAL OF DOXORUBICIN
Total
no.
18
TABLE I.-
No. receiving
3 or more
courses of
doxorubicin
14
and Bachus (1973) report that " four
solid tumour patients developed pro-
gressive CNS disease whilst responding
systemically ".
Of the patients with tumours other
than breast carcinoma, only the man with
reticulum cell sarcoma enjoyed a worth-
while response.
Side-effects.-The list of side-effects is
given in Table II. Epilation was often
TABLE II.-Side-effects due to Doxorubicin
Side-effect Number of patients
Rigors and pyrexia 2
Lethargy 8
Alimentary disturbances 11
Marrow depression 11
Epilation 20
Possible cardiac toxicity 4
gross, requiring a wig. Marrow depres-
sion was marked by a droll in total white
cell count to under 3000/mM3 in 8 patients
(in one it fell to under 1000/mm3); the
nadir occurred in about 14 days with a
return to normal by 21 days. Anaemia,
with a fall in the haemoglobin concentra-
tion to under 9 g/l 00 ml occurred in 6
patients but this could have been due at
least in part to progressive malignancy.
Few biochemical abnormalities were
noted but the lactic acid dehydrogenase
level became raised during treatment in 3
patients.
In view of the known risk of cardiac
toxicity this was sought in each patient.
The fatal form is a cardiomyopathy
characterized by irreversible congestive
failure (Gottlieb et al., 1973), but this was
not observed in this series and no patient
died with cardiac features. Four patients
did have cardiac abnormalities, possibly
due to toxicity. One developed tachy-
cardia after her third dose; the blood
9
-Patients with Breast Carcinoma
No. with some
evidence of response
(including 2 with over No. with more than
50% regression) 50% tumour regression
7 2
pressure fell from 140/100 to 90/60 mm Hg
and her ECG contained flattened " T "
waves with lengthened " QRS " com-
plexes but she was also anaemic and in
poor general condition by this stage.
The second patient developed substernal
pain, aggravated by exercise, after a
single dose but the ECG was normal.
She later underwent cholecystectomy and
there is still doubt about the origin of her
pain. The third patient, who had pre-
viously undergone adrenalectomy, com-
plained of substernal pain and dyspnoea
after a single dose. She was found to
have tachycardia and the blood pressure
fell from 160/90 to 90/60 mm Hg but the
ECG remained normal. Recovery took
place when her dosage of replacement
corticosteroids was increased. The fourth
patient became hypotensive after 2 doses
but she was anaemic, very ill from her
malignancy, and the ECG remained
normal.
DISCUSSION
Blum and Carter (1973), using the
same criteria (50%/ regression sustained
for at least a month in patients who had
had an adequate trial of the drug) score
67/193 (350o) which is better than that
observed in this present small series, but
of the same order as the 350o which they
record for cyclophosphamide, 3500 for
methotrexate and 260% for fluorouracil.
Gottlieb et al. (1973) record an overall
incidence of fatal cardiomyopathy of
about 1% but relate this to dose as the
incidence rises sharply to 21% when the
total dose exceeds 550 mg/M2. This sug-
gests that doxorubicin may best be used
as an induction agent in combination with
other drugs. If the incidence of cerebral
metastases is confirmed, this would pro-
vide an additional reason for combination
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with other drugs or with radiotherapy.
Further, the possibility that the response
rate as well as the risk of cardiomyopathy
may also increase with prolonged dosage
must be kept in mind.
Trials are now in progress to assess the
drug in combination with established
cytotoxic agents in advanced malignant
disease.
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